Wordt geladen...
The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia
PURPOSE: To establish a proof-of-concept for the efficacy of the anti-CD38 antibody daratumumab in the poor prognosis CD38(+) CLL subtype. EXPERIMENTAL DESIGN: The mechanism of action of daratumumab was assessed in CLL primary cells and cell lines using peripheral blood mononuclear cells to analyze...
Bewaard in:
| Gepubliceerd in: | Clin Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5354986/ https://ncbi.nlm.nih.gov/pubmed/27637890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2095 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|